Close Menu

NEW YORK — GNA Biosolutions said on Tuesday that its Octea SARS-CoV-2 batch testing system has received Emergency Use Authorization from the German Federal Institute for Drugs and Medical Devices.

The system is based on a proprietary PCR technology, called pulsed control amplification, that uses short electrical pulses to drive rapid amplification cycles and can amplify nucleic acids directly from samples without additional preparation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.